PA8640601A1 - NEW ANTI-IGF-IR ANTIBODIES AND THEIR USES - Google Patents
NEW ANTI-IGF-IR ANTIBODIES AND THEIR USESInfo
- Publication number
- PA8640601A1 PA8640601A1 PA20058640601A PA8640601A PA8640601A1 PA 8640601 A1 PA8640601 A1 PA 8640601A1 PA 20058640601 A PA20058640601 A PA 20058640601A PA 8640601 A PA8640601 A PA 8640601A PA 8640601 A1 PA8640601 A1 PA 8640601A1
- Authority
- PA
- Panama
- Prior art keywords
- antibodies
- igf
- canceres
- igr
- sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
LA PRESENTE INVENCION SE REFIERE A NUEVOS ANTICUERPOS CAPACES DE UNIRSE ESPECIFICAMENTE AL RECEPTOR IGF-IR DEL FACTOR DE CRECIMIENTO HUMANO SIMILAR A LA INSULINA Y/O CAPACES DE INHIBIR ESPECIFICAMENTE LA ACTIVIDAD TIROSIN-QUINASA DE DICHO IGF-IR, ESPECIALMENTE ANTICUERPOS MONOCLONALES DE ORIGEN MURINO, QUIMERICO O HUMANIZADO, ASI COMO LAS SECUENCIAS DE LOS AMINOACIDOS Y SECUENCIAS DE NUCLEOTIDOS QUE CODIFIQUEN ESTOS ANTICUERPOS. LA INVENCION TAMBIEN ABARCA EL USO DE ESTOS ANTICUERPOS COMO MEDICAMENTO PARA EL TRATAMIENTYO PROFILACTICO Y/O TERAPEUTICO DE CANCERES QUE SOBREEXPRESEN IGF-IGR O CUALQUIER PAROLOGIA CONECTADA CON LA SOBREEXPRESION DE DICHO RECEPTOR, ASI COMO LOS PRECESOS O KITS DE DIAGNOSTICO DE ENFERMEDADES RELACIONADAS CON LA SOBREEXPRESION DE IGF-IGR. LA INVENCION FINALMENTE COMPRENDE LOS PRODUCTOS Y/O LAS COMPOSICIONES QUE ABARQUEN LOS MENCIONADOS ANTICUERPOS EN COMBINACION CON ANTICUERPOS ANTI-EGFR Y/O ANTICUERPOS ANTI-VEGF Y/O ANTICUERPOS DIRIGIDOS CONTRA OTROS FACTORES DE CRECIMIENTO INVOLUCRADOS EN LA PROGRESION DEL TUMOS O MATASTASIS Y/O COMPUESTOS Y/O AGENTES ANTICANCERIGENOS O AGENTES CONJUGADOS CON TOXINAS Y SU USO PARA LA PREVENCION Y/O TRATAMIENTO DE CIERTOS CANCERES.THE PRESENT INVENTION REFERS TO NEW CAPACITY ANTIBODIES TO SPECIFICALLY JOIN THE IGF-IR RECEIVER OF THE HUMAN GROWTH FACTOR SIMILAR TO INSULIN AND / OR CAPACIES TO SPECIFICALLY INHIBIT THE THIROSIN-KINASE ACTIVITY OF SUCH IGF-SPECIAL ORIGINAL ORIGINAL ORIGINAL ORMER , CHEMICAL OR HUMANIZED, AS WELL AS THE SEQUENCES OF AMINO ACIDS AND SEQUENCES OF NUCLEOTIDES THAT CODIFY THESE ANTIBODIES. THE INVENTION ALSO INCLUDES THE USE OF THESE ANTIBODIES AS A MEDICINAL PRODUCT FOR THE PROFILACTIC AND / OR THERAPEUTIC TREATMENT OF CANCERES THAT OVEREXPRESSES IGF-IGR OR ANY PAROLOGY CONNECTED WITH THE OVERPRINTING OF SUCH RECEIVING ASSOCIATED WITH THE RELEASE OF THE KIND OVEREXPRESSION OF IGF-IGR. THE INVENTION FINALLY INCLUDES THE PRODUCTS AND / OR COMPOSITIONS THAT THE ABOVE MENTIONED IN COMBINATION WITH ANTI-EGFR ANTIBODIES AND / OR ANTI-VEGF ANTIBODIES AND / OR ANTIBODIES DIRECTED AGAINST OTHER GROWTH FACTORS INVOLVED IN THE PROGRESS / CONTRIBUTIONS OF OR COMPOUNDS AND / OR ANTI-BANKER AGENTS OR AGENTS CONJUGATED WITH TOXINS AND ITS USE FOR THE PREVENTION AND / OR TREATMENT OF CERTAIN CANCERES.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59193204P | 2004-07-29 | 2004-07-29 | |
FR0408379A FR2873699B1 (en) | 2004-07-29 | 2004-07-29 | NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8640601A1 true PA8640601A1 (en) | 2006-08-03 |
Family
ID=34950307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20058640601A PA8640601A1 (en) | 2004-07-29 | 2005-07-28 | NEW ANTI-IGF-IR ANTIBODIES AND THEIR USES |
Country Status (23)
Country | Link |
---|---|
US (3) | US7854930B2 (en) |
EP (4) | EP2365005A3 (en) |
JP (3) | JP5016487B2 (en) |
KR (1) | KR101220635B1 (en) |
CN (2) | CN103951752A (en) |
AR (1) | AR050036A1 (en) |
AU (1) | AU2005268505B2 (en) |
BR (1) | BRPI0513890A (en) |
CA (1) | CA2575348A1 (en) |
CO (1) | CO5700152A1 (en) |
FR (1) | FR2873699B1 (en) |
GT (1) | GT200500205A (en) |
HK (1) | HK1102600A1 (en) |
IL (2) | IL181025A (en) |
MX (1) | MX2007001109A (en) |
NO (1) | NO20071093L (en) |
NZ (2) | NZ552821A (en) |
PA (1) | PA8640601A1 (en) |
RU (2) | RU2406729C2 (en) |
SV (1) | SV2006002182A (en) |
TW (1) | TWI432451B (en) |
WO (1) | WO2006013472A2 (en) |
ZA (1) | ZA200700593B (en) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
US7553485B2 (en) * | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
EP1622942B1 (en) | 2003-05-01 | 2014-11-19 | ImClone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
WO2005047512A2 (en) | 2003-11-12 | 2005-05-26 | Shering Corporation | Plasmid system for multigene expression |
FR2873699B1 (en) * | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF |
US7811562B2 (en) | 2004-12-03 | 2010-10-12 | Schering Corporation | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
US8128929B2 (en) | 2005-06-17 | 2012-03-06 | Imclone Llc | Antibodies against PDGFRa |
FR2888850B1 (en) * | 2005-07-22 | 2013-01-11 | Pf Medicament | NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS |
AP2008004569A0 (en) | 2006-02-03 | 2008-08-31 | Imclone Systems Inc | IGR-IR antagonists as adjuvants for treatment of prostrate cancer |
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
TW200833711A (en) * | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
MX2009008754A (en) * | 2007-02-14 | 2009-11-02 | Glaxo Group Ltd | Novel antibodies against igf-ir. |
GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
EP2205280B1 (en) | 2007-09-27 | 2019-09-04 | Amgen Inc. | Pharmaceutical formulations |
EP2219602A1 (en) | 2007-11-15 | 2010-08-25 | Amgen, Inc | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
EP2225273B1 (en) | 2007-12-21 | 2012-05-23 | Roche Glycart AG | Stability testing of antibodies |
EP2236139A1 (en) | 2009-03-31 | 2010-10-06 | F. Hoffmann-La Roche AG | Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
US9662271B2 (en) | 2009-10-23 | 2017-05-30 | Amgen Inc. | Vial adapter and system |
BR112012009828B8 (en) | 2009-10-26 | 2022-10-25 | Hoffmann La Roche | METHOD FOR THE PRODUCTION OF A GLYCOSYLED IMMUNOGLOBULIN AND ITS USE |
US8444982B2 (en) * | 2009-12-04 | 2013-05-21 | The University Of Hong Kong | Anti-IGF-IR antibodies and uses thereof |
WO2011101328A2 (en) | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
EA032537B1 (en) | 2010-06-07 | 2019-06-28 | Эмджен Инк. | Method of operation of a drug delivery device |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
ES2865068T3 (en) | 2011-01-14 | 2021-10-14 | Univ California | Therapeutic antibodies to ROR-1 protein and methods of using them |
EP2671082B1 (en) | 2011-02-02 | 2020-01-15 | Amgen Inc. | Methods and compositons relating to inhibition of igf-1r |
MX341790B (en) | 2011-03-31 | 2016-09-02 | Amgen Inc | Vial adapter and system. |
JP6038884B2 (en) | 2011-04-20 | 2016-12-07 | アムゲン・インコーポレーテッド | Automatic injection device |
LT3045189T (en) | 2011-10-14 | 2018-06-25 | Amgen Inc. | Injector and method of assembly |
EP2776042B1 (en) | 2011-11-11 | 2019-03-20 | Duke University | Combination drug therapy for the treatment of solid tumors |
EP2631653A1 (en) | 2012-02-24 | 2013-08-28 | Charité - Universitätsmedizin Berlin | Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family |
EP2863947B1 (en) * | 2012-06-21 | 2018-03-07 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind igf1r |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
CN102830223A (en) * | 2012-08-14 | 2012-12-19 | 四川汇宇制药有限公司 | Screening method for drugs used for treating neoplastic diseases in mammals |
EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
WO2014067642A1 (en) | 2012-11-05 | 2014-05-08 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
EP4234694A3 (en) | 2012-11-21 | 2023-09-06 | Amgen Inc. | Drug delivery device |
JP6768501B2 (en) | 2013-03-15 | 2020-10-14 | アムゲン・インコーポレーテッド | Drug cassettes, automatic injection machines, and automatic injection machine systems |
JP6336564B2 (en) | 2013-03-15 | 2018-06-06 | アムゲン・インコーポレーテッド | Drug cassette, auto-injector, and auto-injector system |
AU2014238267B2 (en) | 2013-03-22 | 2019-08-15 | Amgen Inc. | Injector and method of assembly |
AU2014317884B2 (en) | 2013-09-09 | 2017-09-07 | Canimguide Therapeutics Ab | Immune system modulators |
JP7051293B2 (en) | 2013-10-24 | 2022-04-11 | アムジエン・インコーポレーテツド | Drug delivery system with temperature sensing control |
KR102458637B1 (en) | 2013-10-24 | 2022-10-24 | 암겐 인코포레이티드 | Injector and method of assembly |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
CN112851808A (en) * | 2014-04-25 | 2021-05-28 | 皮埃尔法布雷医药公司 | IGF-1R antibodies and their use as localization vectors for the treatment of cancer |
CA3193070A1 (en) | 2014-05-07 | 2015-11-12 | Amgen Inc. | Autoinjector with shock reducing elements |
SG11201609963PA (en) | 2014-06-03 | 2016-12-29 | Amgen Inc | Devices and methods for assisting a user of a drug delivery device |
US10695506B2 (en) | 2014-10-14 | 2020-06-30 | Amgen Inc. | Drug injection device with visual and audio indicators |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
JP2017538512A (en) | 2014-12-19 | 2017-12-28 | アムジエン・インコーポレーテツド | Drug delivery device including live button or user interface field |
MX2017010466A (en) | 2015-02-17 | 2018-06-06 | Amgen Inc | Drug delivery device with vacuum assisted securement and/or feedback. |
EP3981450A1 (en) | 2015-02-27 | 2022-04-13 | Amgen, Inc | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
ES2853582T3 (en) | 2015-03-06 | 2021-09-16 | Canimguide Therapeutics Ab | Immune system modulators and compositions |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
JP7082568B2 (en) | 2015-12-09 | 2022-06-08 | アムジエン・インコーポレーテツド | Automatic syringe with signal transduction cap |
WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
NZ743881A (en) | 2016-02-06 | 2023-11-24 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
ES2814287T3 (en) | 2016-03-15 | 2021-03-26 | Amgen Inc | Reduce the likelihood of glass breakage in drug delivery devices |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
ES2959783T3 (en) | 2016-05-13 | 2024-02-28 | Amgen Inc | Vial Protective Cover Assembly |
EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
CA3049780A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
JP7064501B2 (en) | 2017-02-17 | 2022-05-10 | アムジエン・インコーポレーテツド | Drug delivery device with sterile fluid flow path and related assembly methods |
JP7280189B2 (en) | 2017-02-17 | 2023-05-23 | アムジエン・インコーポレーテツド | Insertion mechanism for drug delivery device |
EP3592403A1 (en) | 2017-03-06 | 2020-01-15 | Amgen Inc. | Drug delivery device with activation prevention feature |
CA3052482A1 (en) | 2017-03-07 | 2018-09-13 | Amgen Inc. | Needle insertion by overpressure |
IL268386B2 (en) | 2017-03-09 | 2023-11-01 | Amgen Inc | Insertion mechanism for drug delivery device |
CN114588404A (en) | 2017-03-28 | 2022-06-07 | 美国安进公司 | Plunger rod and syringe assembly systems and methods |
EP3634546A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Torque driven drug delivery device |
US11590294B2 (en) | 2017-06-08 | 2023-02-28 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
JP7195276B2 (en) | 2017-06-22 | 2022-12-23 | アムジエン・インコーポレーテツド | Collision/shock reduction due to device activation |
WO2018237225A1 (en) | 2017-06-23 | 2018-12-27 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
JP7408398B2 (en) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | Needle insertion and retraction system with dual torsion spring system |
WO2019018169A1 (en) | 2017-07-21 | 2019-01-24 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
EP3658203B1 (en) | 2017-07-25 | 2022-08-31 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
US11484648B2 (en) | 2017-07-25 | 2022-11-01 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
WO2019032482A2 (en) | 2017-08-09 | 2019-02-14 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | Flow adapter for drug delivery device |
EP4257164A3 (en) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
EP3694578A1 (en) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
WO2019090086A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
MA50569A (en) | 2017-11-06 | 2020-09-16 | Amgen Inc | FILLING-FINISHING UNITS AND ASSOCIATED PROCESSES |
JP2021501616A (en) | 2017-11-06 | 2021-01-21 | アムジエン・インコーポレーテツド | Drug delivery device with placement and flow detection |
US11191904B2 (en) | 2017-11-10 | 2021-12-07 | Amgen Inc. | Plungers for drug delivery devices |
MA50904A (en) | 2017-11-16 | 2020-09-23 | Amgen Inc | NEEDLE INSERTION MECHANISM FOR DRUG DELIVERY DEVICE |
MA50903A (en) | 2017-11-16 | 2021-05-12 | Amgen Inc | SELF-INJECTOR WITH STALL AND END POINT DETECTION |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
EP3826699A1 (en) | 2018-07-24 | 2021-06-02 | Amgen Inc. | Delivery devices for administering drugs |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020023444A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
EP3829692A1 (en) | 2018-07-31 | 2021-06-09 | Amgen Inc. | Fluid path assembly for a drug delivery device |
MA53724A (en) | 2018-09-24 | 2021-12-29 | Amgen Inc | INTERVENTIONAL DOSING SYSTEMS AND METHODS |
CA3110371A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
CA3110529A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
WO2020072846A1 (en) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Drug delivery device having dose indicator |
EA202191037A1 (en) | 2018-10-15 | 2021-08-05 | Эмджен Инк. | A DRUG DELIVERY DEVICE WITH A DAMPER MECHANISM |
AR116703A1 (en) | 2018-10-15 | 2021-06-02 | Amgen Inc | PLATFORM ASSEMBLY PROCESS FOR A DRUG MANAGEMENT DEVICE |
MA54048A (en) | 2018-11-01 | 2022-02-09 | Amgen Inc | DRUG DELIVERY DEVICES WITH PARTIAL RETRACTION OF DRUG DELIVERY BODY |
TWI831847B (en) | 2018-11-01 | 2024-02-11 | 美商安進公司 | Drug delivery devices with partial needle retraction and methods for operating the same |
MA54057A (en) | 2018-11-01 | 2022-02-09 | Amgen Inc | DRUG DELIVERY ELEMENT PARTIAL RETRACTION DRUG DELIVERY DEVICES |
JP2022529319A (en) | 2019-04-24 | 2022-06-21 | アムジエン・インコーポレーテツド | Syringe sterility confirmation assembly and method |
EP4017560A2 (en) | 2019-08-23 | 2022-06-29 | Amgen, Inc | Drug delivery device with configurable needle shield engagement components and related methods |
WO2022086620A1 (en) * | 2020-10-20 | 2022-04-28 | The Methodist Hospital System | Psma-targeted immunotherapies for cancers |
BR112023024278A2 (en) | 2021-05-21 | 2024-01-30 | Amgen Inc | METHOD OF OPTIMIZING A FILLING RECIPE FOR A DRUG CONTAINER |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (en) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE |
US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
EP1261371A4 (en) * | 2000-02-25 | 2005-04-13 | Univ California | Membrane estrogen receptor-directed therapy in breast cancer |
HUP0302525A2 (en) * | 2001-01-05 | 2003-10-28 | Abgenix, Inc. | Antibodies to insulin-like growth factor i receptor |
US20080193445A1 (en) * | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
US20080063639A1 (en) * | 2002-01-18 | 2008-03-13 | Pierre Fabre Medicament | Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies |
US7553485B2 (en) * | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
CA2473039C (en) * | 2002-01-18 | 2014-09-23 | Pierre Fabre Medicament | Novel anti-igf-ir antibodies and uses thereof |
NZ571508A (en) * | 2002-05-24 | 2010-05-28 | Schering Corp | Neutralizing human anti-IGFR antibody |
US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
GB0219524D0 (en) * | 2002-08-21 | 2002-10-02 | Queen Mary & Westfield College | Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor |
JP4473257B2 (en) * | 2003-04-02 | 2010-06-02 | エフ.ホフマン−ラ ロシュ アーゲー | Antibodies against insulin-like growth factor I receptor and uses thereof |
MXPA06001634A (en) * | 2003-08-13 | 2006-04-28 | Pfizer Prod Inc | Modified human igf-1r antibodies. |
FR2873699B1 (en) * | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF |
FR2888850B1 (en) * | 2005-07-22 | 2013-01-11 | Pf Medicament | NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS |
FR2907341B1 (en) * | 2006-10-18 | 2012-08-17 | Pf Medicament | USE OF ANTI-CD151 ANTIBODY FOR THE TREATMENT OF CANCER |
-
2004
- 2004-07-29 FR FR0408379A patent/FR2873699B1/en not_active Expired - Fee Related
-
2005
- 2005-07-27 MX MX2007001109A patent/MX2007001109A/en active IP Right Grant
- 2005-07-27 CN CN201310216929.3A patent/CN103951752A/en active Pending
- 2005-07-27 BR BRPI0513890-6A patent/BRPI0513890A/en not_active IP Right Cessation
- 2005-07-27 RU RU2007107589/10A patent/RU2406729C2/en not_active IP Right Cessation
- 2005-07-27 EP EP20110161875 patent/EP2365005A3/en not_active Withdrawn
- 2005-07-27 WO PCT/IB2005/002619 patent/WO2006013472A2/en active Application Filing
- 2005-07-27 CN CN2005800251969A patent/CN101014625B/en not_active Expired - Fee Related
- 2005-07-27 NZ NZ552821A patent/NZ552821A/en not_active IP Right Cessation
- 2005-07-27 NZ NZ569718A patent/NZ569718A/en not_active IP Right Cessation
- 2005-07-27 KR KR1020077004904A patent/KR101220635B1/en not_active IP Right Cessation
- 2005-07-27 EP EP20110161877 patent/EP2380912A1/en not_active Withdrawn
- 2005-07-27 JP JP2007523178A patent/JP5016487B2/en not_active Expired - Fee Related
- 2005-07-27 CA CA002575348A patent/CA2575348A1/en not_active Abandoned
- 2005-07-27 EP EP05780625.9A patent/EP1771481B1/en active Active
- 2005-07-27 US US11/658,739 patent/US7854930B2/en not_active Expired - Fee Related
- 2005-07-27 EP EP11161878A patent/EP2365006A3/en not_active Withdrawn
- 2005-07-27 AU AU2005268505A patent/AU2005268505B2/en not_active Ceased
- 2005-07-28 GT GT200500205A patent/GT200500205A/en unknown
- 2005-07-28 CO CO05074351A patent/CO5700152A1/en not_active Application Discontinuation
- 2005-07-28 TW TW094125515A patent/TWI432451B/en not_active IP Right Cessation
- 2005-07-28 PA PA20058640601A patent/PA8640601A1/en unknown
- 2005-07-29 SV SV2005002182A patent/SV2006002182A/en not_active Application Discontinuation
- 2005-07-29 AR ARP050103179A patent/AR050036A1/en not_active Application Discontinuation
-
2007
- 2007-01-22 ZA ZA200700593A patent/ZA200700593B/en unknown
- 2007-01-29 IL IL181025A patent/IL181025A/en not_active IP Right Cessation
- 2007-02-27 NO NO20071093A patent/NO20071093L/en not_active Application Discontinuation
- 2007-10-05 HK HK07110853.8A patent/HK1102600A1/en not_active IP Right Cessation
-
2009
- 2009-10-21 RU RU2009138977/10A patent/RU2009138977A/en not_active Application Discontinuation
-
2010
- 2010-12-20 US US12/973,480 patent/US8124079B2/en not_active Expired - Fee Related
-
2012
- 2012-01-18 US US13/352,976 patent/US8420085B2/en not_active Expired - Fee Related
- 2012-02-24 JP JP2012038645A patent/JP2012153692A/en active Pending
-
2013
- 2013-12-03 IL IL229778A patent/IL229778A0/en unknown
-
2014
- 2014-03-17 JP JP2014053009A patent/JP2014193862A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8640601A1 (en) | NEW ANTI-IGF-IR ANTIBODIES AND THEIR USES | |
AR054175A1 (en) | NEW ANTI-IGF-IR ANTIBODIES AND USES OF THE SAME | |
WO2003059951A8 (en) | Novel anti-igf-ir antibodies and uses thereof | |
AR080685A1 (en) | COMPOSITIONS OF ANTI-FACTOR ANTI-FACTOR OF NERVOUS GROWTH (NGF) | |
TW200606162A (en) | Pyrazolopyridine derivatives | |
UA94899C2 (en) | Fixed dosing of her antibodies | |
CO6351727A2 (en) | PIRIDAZINE DERIVATIVES AS SMO INHIBITORS | |
GEP20196963B (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
CL2009000697A1 (en) | Compounds derived from substituted 2-heteroaryl-6-phenyl-imidazol [1,2-a] pyridines; not receptor modulators; intermediate compounds; preparation procedure; pharmaceutical composition; and use in the treatment of cancer, inflammation, neurodegenerative and psychiatric diseases, epilepsy, among others. | |
MX2010001378A (en) | Therapeutic use of anti-tweak receptor antibodies. | |
MY155649A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
ECSP088298A (en) | MODULATION OF GLUCOCORTICOID RECEIVER EXPRESSION | |
BRPI0508820A (en) | compounds as opioid receptor modulators | |
EA200800564A1 (en) | DERIVATIVES OF XANTHINE AS SELECTIVE AGONISTS NM74A | |
MX2010005651A (en) | Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof. | |
NI201200134A (en) | AGONIST POLYPEPTIDES THAT BIND TO DR5 | |
AR071304A1 (en) | ANTIBODIES ANTI CD151 (FLBR MEMBRANE PROTEIN. OF TETRASPANINS) USEFUL FOR CANCER TREATMENT | |
MY147890A (en) | 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer | |
MX2010010505A (en) | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes. | |
CL2011000119A1 (en) | Compounds derived from triazolo [4,3-a] pyridine; preparation procedure; pharmaceutical composition; and use in the treatment of diseases such as cancer. | |
WO2004091490A3 (en) | Somatostatin-dopamine chimeric analogs | |
MX2009013205A (en) | Therapeutic pyrazoloquinoline urea derivatives. | |
MX2009013202A (en) | Therapeutic pyrazoloquinoline derivatives. | |
MX2009013197A (en) | Therapeutic pyrazolonaphthyridine derivatives. | |
MX2014002762A (en) | Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients. |